GovChime
Archived

Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

Overview

Response deadline
12:00 PM CDT
Posted
February 10, 2026
Notice type
Solicitation
Set-aside
No Set aside used
Agency
Department of WarDEFENSE HEALTH AGENCY (DHA)

Notice details

Office
DEFENSE HEALTH AGENCY (DHA)
Place of performance
San Antonio, Texas, 78230
Last updated
Nov 4, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
HT9402-26-Q-9201
Notice ID
fe66d512d41448bb81e795cdc32fc134

Description

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P& T COMMITTEE MEETING: The following MAY 2026 drug classes/subclasses will be reviewed: 

a.  Antihemophilic Agents - Non-Factor Agents

  • ALHEMO PEN
  • HEMLIBRA
  • HYMPAVZI PEN
  • QFITLIA

b.  Leukemia and Lymphoma - BCR-ABL-TKI

  • BOSULIF
  • DANZITEN
  • ICLUSIG
  • IMKELDI
  • PHYRAGO
  • SCEMBLIX
  • SPRYCEL
  • TASIGNA
  • NILOTINIB TARTRATE

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9201. Pre-quotation teleconference is on February 11, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

Files (5)

  • RFQ HT9402-26-Q-9201 CR.pdf

    1.6 MBAdded in Solicitation version 1Posted
    Download
  • A-3 NDC Price List Antihemophilic Ag - Non-Fac Ag.xlsx

    47 KBAdded in Solicitation version 1Posted
    Download
  • A-3 NDC Price List Leukemia and Lymphoma - BCR-ABL-TKI.xlsx

    47 KBAdded in Solicitation version 1Posted
    Download
  • May 2026 PT Meeting Reporting.xlsx

    136 KBAdded in Solicitation version 1Posted
    Download
  • NDC Price List FAQ Class Review.pdf

    227 KBAdded in Solicitation version 1Posted
    Download

Lifecycle

  1. 1
    Version 1SolicitationArchived

    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

    Notice 832e20c89c0b4f549a4550a833b16cef on SAM.gov

  2. 3
    Version 3SolicitationArchivedCurrent

    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

    Notice fe66d512d41448bb81e795cdc32fc134 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

HT9402-26-Q-9201

Archive Date

Oct 2, 2026

Office Address

JBSA FT SAM HOUSTON, TX, 78234